The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

large cell panels were necessary to provide coverage for detecting the most common HLA antigens. Rare or unusual antigens were frequently not included in most clinical laboratory panels ...

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

This is the result of an elegant evolutionary process that equipped T cells with a sophisticated surveillance system: the human leukocyte antigen (HLA) presentation pathway. When the proteasome breaks ...

In an article published in Nature Cancer, a multi-institutional research team led by the University of Osaka describes how a molecule called HLA-DRB1 can be used as a target for chimeric antigen ...

a multi-institutional research team led by The University of Osaka describes how a molecule called HLA-DRB1 can be used as a target for chimeric antigen receptor (CAR)-based therapy for AML.

Positioning of Diamyd® Positioning of Diamyd ® Diamyd® is a precision immunotherapy targeting individuals with a specific HLA genotype associated with Type 1 Diabetes. Over 1,000 patients have been ...

Individual microparticles are coated with a full HLA class I (HLA-A, -B and -C antigens) or HLA class II type (HLA-DR, -DQB, -DQA and -DP antigens). The specificity assay based on flow cytometry ...

Therefore, many drugs are designed to target tumor-specific antigens, which are molecules ... the researchers determined that KG2032 bound to HLA-DRB1. "Interestingly, we found that KG2032 reacted ...